izpis_h1_title_alt

Non-animal glioblastoma models for personalized treatment
ID Zottel, Alja (Author), ID Jovchevska, Ivana (Author), ID Šamec, Neja (Author)

.pdfPDF - Presentation file, Download (2,11 MB)
MD5: 0FE6347909E948C36AB99DF4CCE276BC
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S2405844023082786 This link opens in a new window

Abstract
Glioblastoma is an extremely lethal cancer characterized by great heterogeneity at different molecular and cellular levels. As a result, treatment options have moved far from systemic and universal therapies toward targeted treatments and personalized medicine. However, for successful translation from preclinical studies to clinical trials, experiments must be performed on reliable disease models. Numerous experimental models have been developed for glioblastoma, ranging from simple 2D cell cultures to study the nature of the disease to complex 3D models such as neurospheres, organoids, tissue-slice cultures, bioprinted models, and tumor on chip, as perfect prototypes to evaluate the therapeutic potential of different drugs. The presence of multiple research models is consistent with the complexity and molecular diversity of glioblastoma. The advantage of such models is the recapitulation of the tumor environment, and in some cases the preservation of immune system components as well as the creation of simple vessels. There are also two case studies translating in vitro studies on glioblastoma organoids to patients as well as four ongoing clinical trials using glioblastoma models, indicating high clinical potential of glioblastoma models.

Language:English
Keywords:glioblastoma, heterogeneity, non-animal models, treatmet predicition
Work type:Article
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2023
Number of pages:9 str.
Numbering:Vol. 9, iss. 10, art. e21070
PID:20.500.12556/RUL-152948 This link opens in a new window
UDC:616-006:577.2
ISSN on article:2405-8440
DOI:10.1016/j.heliyon.2023.e21070 This link opens in a new window
COBISS.SI-ID:170364419 This link opens in a new window
Publication date in RUL:13.12.2023
Views:147
Downloads:16
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Heliyon
Publisher:Elsevier
ISSN:2405-8440
COBISS.SI-ID:21607432 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:glioblastom, heterogenost, neživalski modeli, napoved zdravljenja

Projects

Funder:ARRS - Slovenian Research Agency
Project number:Z3-2649
Name:Določitev novih biomarkerjev glioblastoma za namen neinvazivne tekočinske biopsije

Funder:ARRS - Slovenian Research Agency
Project number:Z3-4510
Name:Vpliv imunoterapije z anti-PD-L1 atezolizumabom in nanotelesom Nb202 na organoide glioblastoma, pripravljene iz tkiva bolnikov

Funder:ARRS - Slovenian Research Agency
Project number:P1-0390
Name:Funkcijska genomika in biotehnologija za zdravje

Funder:Other - Other funder or multiple funders
Funding programme:CELSA
Name:Generation of nanobodies against immunomodulating checkpoint receptors in glioblastoma tumor cells

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back